Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Unsettling Developments for Plavix

This article was originally published in RPM Report

Executive Summary

Bristol-Myers Squibb Co. and Sanofi-Aventis are anxiously awaiting the outcome of an antitrust review of a proposed patent settlement with Apotex Inc. over the timing of a generic launch of clopidogrel (Plavix). They have reason to sweat: it sounds like the Federal Trade Commission is spoiling for a fight.

You may also be interested in...

The War on Generics - Part I

Generic drug companies are riding high after the largest generic launch ever (Zocor) and arguably the cleverest (Plavix). But brand companies are fighting back, and they may succeed in taking away the biggest incentive fueling patent challenges.

Generic Plavix: As Bristol Swoons, Broad Implications

The immediate ramifications of Bristol and Sanofi's failed authorized generics strategy around Plavix may cripple Bristol, hobble, Sanofi, and make a mint for Canadian generics player Apotex. But the most significant impact may be felt in the long term along the fault line where branded and generics companies meet, compete, and increasingly, deal.

The Provigil Vigil

After the Plavix debacle, the Federal Trade Commission, and investors, are wondering about Cephalon's lifeblood Provigil. Cephalon says there's nothing to worry about.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts